MX347372B - Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa. - Google Patents

Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa.

Info

Publication number
MX347372B
MX347372B MX2012013617A MX2012013617A MX347372B MX 347372 B MX347372 B MX 347372B MX 2012013617 A MX2012013617 A MX 2012013617A MX 2012013617 A MX2012013617 A MX 2012013617A MX 347372 B MX347372 B MX 347372B
Authority
MX
Mexico
Prior art keywords
metformin
glucokinase activator
activator
combination
compositions
Prior art date
Application number
MX2012013617A
Other languages
English (en)
Other versions
MX2012013617A (es
Inventor
M M Mjalli Adnan
Carmen Valcarce Lopez Maria
Original Assignee
Vtv Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc filed Critical Vtv Therapeutics Llc
Publication of MX2012013617A publication Critical patent/MX2012013617A/es
Publication of MX347372B publication Critical patent/MX347372B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención proporciona usos de un activador de glucoquinasa en combinación con metformina. Los usos incluyen el tratamiento de diabetes tipo 2, la disminución de la glucosa en sangre, el mejoramiento de la sensibilidad a la insulina, el mejoramiento de la fosforilación de la glucosa y el mejoramiento de la eficacia terapéutica de metformina. La invención también proporciona composiciones farmacéuticas que comprenden un activador de GK y metformina. La invención también proporciona una sal formada entre metformina y un activador de GK.
MX2012013617A 2010-05-26 2011-05-24 Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa. MX347372B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34855410P 2010-05-26 2010-05-26
PCT/US2011/037752 WO2011149945A1 (en) 2010-05-26 2011-05-24 Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator

Publications (2)

Publication Number Publication Date
MX2012013617A MX2012013617A (es) 2013-03-20
MX347372B true MX347372B (es) 2017-04-25

Family

ID=45004334

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013617A MX347372B (es) 2010-05-26 2011-05-24 Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa.

Country Status (30)

Country Link
US (4) US9359313B2 (es)
EP (1) EP2576524B1 (es)
JP (1) JP5902676B2 (es)
KR (2) KR101860120B1 (es)
CN (1) CN102906077B (es)
AU (1) AU2011258460B2 (es)
BR (1) BR112012029844A2 (es)
CA (1) CA2799591C (es)
CO (1) CO6640324A2 (es)
CY (1) CY1119850T1 (es)
DK (1) DK2576524T3 (es)
EA (1) EA032085B1 (es)
ES (1) ES2655396T3 (es)
HR (1) HRP20180113T1 (es)
HU (1) HUE036009T2 (es)
IL (1) IL223137A0 (es)
LT (1) LT2576524T (es)
ME (1) ME03007B (es)
MX (1) MX347372B (es)
NO (1) NO2576524T3 (es)
NZ (1) NZ603614A (es)
PE (1) PE20130275A1 (es)
PL (1) PL2576524T3 (es)
PT (1) PT2576524T (es)
RS (1) RS56761B1 (es)
SG (1) SG185660A1 (es)
SI (1) SI2576524T1 (es)
SM (1) SMT201800140T1 (es)
TW (1) TWI508723B (es)
WO (1) WO2011149945A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2576524T (pt) * 2010-05-26 2017-11-17 Vtv Therapeutics Llc Resumo
IN2014DN09554A (es) * 2012-05-17 2015-07-17 Transtech Pharma Llc
CA2903433A1 (en) * 2013-03-04 2014-09-12 Vtv Therapeutics Llc Stable glucokinase activator compositions
HK1213197A1 (zh) * 2013-03-04 2016-06-30 Vtv治疗有限责任公司 包括葡糖激酶活化劑的固體組合物及其製備和使用方法
CN110167542A (zh) * 2016-11-09 2019-08-23 诺沃梅迪科斯有限公司 1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法
BR112020024269A2 (pt) * 2018-05-31 2021-02-23 Hua Medicine (Shanghai) Ltd. combinação farmacêutica, composição e formulação de combinação contendo ativador de glucoquinase e ativador de receptor ppar e métodos de preparação e usos dos mesmos
CA3093025A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CA3181665A1 (en) * 2020-06-08 2021-12-16 Jing TENG Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof
US12479808B2 (en) 2020-06-08 2025-11-25 Vtv Therapeutics Llc Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof
CN115073331A (zh) * 2021-03-15 2022-09-20 中国医学科学院药物研究所 二甲双胍肉桂酸盐一水合物及制备方法和其组合物与用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT323195B (de) * 1973-03-16 1975-06-25 Hurka Wilhelm Verfahren zur herstellung neuer salze von biguaniden
FR2243684B1 (es) * 1973-09-19 1977-01-28 Semb
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
CA2744893A1 (en) * 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
ITRM20030053A1 (it) * 2003-02-10 2004-08-11 Sigma Tau Ind Farmaceuti Associazione di farmaci antidiabetici.
WO2005023766A1 (en) 2003-09-11 2005-03-17 Biocon Limited Salt of atorvastatin with metformin
BRPI0506662B8 (pt) * 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
AU2005291810B2 (en) * 2004-10-07 2011-12-08 Stem Cell Therapeutics Corp. Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds
JP2009500378A (ja) * 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素
JP2009500377A (ja) * 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス ジシクロアルキルウレア型グルコキナーゼ活性化剤
JP4960355B2 (ja) * 2005-07-14 2012-06-27 ノボ・ノルデイスク・エー／エス ウレア型グルコキナーゼ活性化剤
JP2010515701A (ja) * 2007-01-09 2010-05-13 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
JP5513492B2 (ja) 2008-05-16 2014-06-04 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
KR101190957B1 (ko) * 2009-08-25 2012-10-15 한올바이오파마주식회사 메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
PT2576524T (pt) * 2010-05-26 2017-11-17 Vtv Therapeutics Llc Resumo
IN2014DN09554A (es) 2012-05-17 2015-07-17 Transtech Pharma Llc
CA2903433A1 (en) 2013-03-04 2014-09-12 Vtv Therapeutics Llc Stable glucokinase activator compositions
HK1213197A1 (zh) 2013-03-04 2016-06-30 Vtv治疗有限责任公司 包括葡糖激酶活化劑的固體組合物及其製備和使用方法

Also Published As

Publication number Publication date
IL223137A0 (en) 2013-02-03
US9855251B2 (en) 2018-01-02
CN102906077A (zh) 2013-01-30
WO2011149945A1 (en) 2011-12-01
US10363244B2 (en) 2019-07-30
SI2576524T1 (en) 2018-01-31
PE20130275A1 (es) 2013-03-17
SG185660A1 (en) 2012-12-28
US9359313B2 (en) 2016-06-07
CN102906077B (zh) 2015-03-04
SMT201800140T1 (it) 2018-05-02
NO2576524T3 (es) 2018-03-24
ES2655396T3 (es) 2018-02-19
KR101878252B1 (ko) 2018-07-13
HRP20180113T1 (hr) 2018-02-23
US20170354647A1 (en) 2017-12-14
EA201201617A1 (ru) 2013-04-30
US20110313007A1 (en) 2011-12-22
EA032085B1 (ru) 2019-04-30
PT2576524T (pt) 2017-11-17
TWI508723B (zh) 2015-11-21
PL2576524T3 (pl) 2018-03-30
HUE036009T2 (hu) 2018-06-28
EP2576524A1 (en) 2013-04-10
CY1119850T1 (el) 2018-06-27
MX2012013617A (es) 2013-03-20
EP2576524A4 (en) 2014-03-05
ME03007B (me) 2018-10-20
JP2013526608A (ja) 2013-06-24
KR20180028539A (ko) 2018-03-16
RS56761B1 (sr) 2018-04-30
US10064846B2 (en) 2018-09-04
AU2011258460A1 (en) 2013-01-10
US20160184277A1 (en) 2016-06-30
HK1181044A1 (en) 2013-11-01
AU2011258460B2 (en) 2015-02-19
CO6640324A2 (es) 2013-03-22
US20180344706A1 (en) 2018-12-06
BR112012029844A2 (pt) 2015-10-13
EP2576524B1 (en) 2017-10-25
TW201201791A (en) 2012-01-16
CA2799591A1 (en) 2011-12-01
CA2799591C (en) 2019-06-11
KR101860120B1 (ko) 2018-05-23
DK2576524T3 (en) 2018-01-22
LT2576524T (lt) 2017-12-27
NZ603614A (en) 2014-10-31
JP5902676B2 (ja) 2016-04-13
KR20130109015A (ko) 2013-10-07

Similar Documents

Publication Publication Date Title
EA201201617A1 (ru) Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы
EA201100621A1 (ru) Лечение диабета у пациентов, у которых наблюдается недостаточный гликемический контроль несмотря на лечение пероральным или непероральным противодиабетическим лекарственным средством
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
EA201170149A1 (ru) Новые аналоги инсулина пролонгированной активности
EA201491934A1 (ru) Аналоги глюкагоноподобного пептида-2 (glp-2)
EA201991014A1 (ru) Лечение диабета
MX2012006734A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
MX2011007397A (es) Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos.
MX362503B (es) Combinacion farmaceutica para mejorar el control glucemico como terapia adicional a la insulina basal.
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
MX2013013307A (es) Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
MX360304B (es) Composiciones de activador de glucocinasa para el tratamiento de la diabetes.
MX2015008555A (es) Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.
IL207720A0 (en) Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
JOP20210201A1 (ar) مركب لخفض جلوكوز الدم
MY152172A (en) Therapeutic agent for diabetes
PH12019502655A1 (en) Acylated insulin compound
MY154376A (en) A transdermal fluid
MX2020002312A (es) Farmaceutica combinada que comprende dapagliflozina l-prolina y metformina.
MX2014001271A (es) Tratamiento de diabetes de tipo 2 con fty720.
JO3333B1 (ar) استعمال 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium أو ملح مقبول دوائيا منه للوقاية من السكري وعلاجه

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: VTV THERAPEUTICS LLC

HC Change of company name or juridical status

Owner name: VTV THERAPEUTICS LLC

GB Transfer or rights

Owner name: VTV THERAPEUTICS LLC

HC Change of company name or juridical status

Owner name: VTV THERAPEUTICS LLC

FG Grant or registration